Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Eckstein

Showing results (231-240 of 238) with videos related to

Pageof 24
Sort By:
You have reached the last page of results.This site can display upto 238 results.
The Lancet. Rheumatology|November 14, 2024
CD19-targeting CAR T-cell therapy in patients with diffuse systemic sclerosis: a case seriesJanina Auth, Fabian Müller, Simon Völkl, et al.
BJU International|February 7, 2023
Prognostic impact of variant histologies in urothelial bladder cancer treated with radical cystectomyFrancesco Claps, Maaike W van de Kamp, Roman Mayr, et al.
Iscience|January 27, 2025
Deep learning uncovers histological patterns of YAP1/TEAD activity related to disease aggressiveness in cancer patientsBenoit Schmauch, Vincent Cabeli, Omar Darwiche Domingues, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 19, 2022
Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin ResistanceNiklas Klümper, Damian J Ralser, Jörg Ellinger, et al.
European Urology|July 20, 2020
FGFR3 Mutation Status and FGFR3 Expression in a Large Bladder Cancer Cohort Treated by Radical Cystectomy: Implications for Anti-FGFR3 Treatment?<sup>†</sup>Bas W G van Rhijn, Laura S Mertens, Roman Mayr, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 24, 2024
<i>NECTIN4</i> Amplification Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial CancerNiklas Klümper, Ngoc Khanh Tran, Stefanie Zschäbitz, et al.
Urologic Oncology|December 15, 2021
Prognostic markers in invasive bladder cancer: FGFR3 mutation status versus P53 and KI-67 expression: a multi-center, multi-laboratory analysis in 1058 radical cystectomy patientsLaura S Mertens, Francesco Claps, Roman Mayr, et al.
Communications Biology|November 9, 2022
A genome-wide association study with tissue transcriptomics identifies genetic drivers for classic bladder exstrophyEnrico Mingardo, Glenda Beaman, Philip Grote, et al.
Pageof 24

Showing results (231-240 of 238) with videos related to

Sort By:
Pageof 24
You have reached the last page of results.This site can display upto 238 results.
The Lancet. Rheumatology|November 14, 2024
CD19-targeting CAR T-cell therapy in patients with diffuse systemic sclerosis: a case seriesJanina Auth, Fabian Müller, Simon Völkl, et al.
BJU International|February 7, 2023
Prognostic impact of variant histologies in urothelial bladder cancer treated with radical cystectomyFrancesco Claps, Maaike W van de Kamp, Roman Mayr, et al.
Iscience|January 27, 2025
Deep learning uncovers histological patterns of YAP1/TEAD activity related to disease aggressiveness in cancer patientsBenoit Schmauch, Vincent Cabeli, Omar Darwiche Domingues, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 19, 2022
Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin ResistanceNiklas Klümper, Damian J Ralser, Jörg Ellinger, et al.
European Urology|July 20, 2020
FGFR3 Mutation Status and FGFR3 Expression in a Large Bladder Cancer Cohort Treated by Radical Cystectomy: Implications for Anti-FGFR3 Treatment?<sup>†</sup>Bas W G van Rhijn, Laura S Mertens, Roman Mayr, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 24, 2024
<i>NECTIN4</i> Amplification Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial CancerNiklas Klümper, Ngoc Khanh Tran, Stefanie Zschäbitz, et al.
Urologic Oncology|December 15, 2021
Prognostic markers in invasive bladder cancer: FGFR3 mutation status versus P53 and KI-67 expression: a multi-center, multi-laboratory analysis in 1058 radical cystectomy patientsLaura S Mertens, Francesco Claps, Roman Mayr, et al.
Communications Biology|November 9, 2022
A genome-wide association study with tissue transcriptomics identifies genetic drivers for classic bladder exstrophyEnrico Mingardo, Glenda Beaman, Philip Grote, et al.
Pageof 24